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Transcatheter aortic valve implantation (TAVI) has become the method of choice for 
patients with severe aortic valve stenosis, who are ineligible or at high risk for surgery. 
In this high risk patient population, early and late mortality and rehospitalization rates 
after TAVI are still relatively high. In spite of recent improvements in procedural TAVI, 
and establishment of risk models for poor outcome, determining individual risk remains 
challenging. In this context, current data from several small studies strongly suggest 
that blood biomarkers of myocardial injury, cardiac mechanical stretch, inflammation, 
and hemostasis imbalance might play an important role by providing informations on 
patient risk at baseline, and postprocedural progression of patient clinical conditions from 
days up to years post-TAVI. Although the role of biomarkers for predicting survival post-
TAVI remains to be validated in large randomized studies, implementing biomarkers in 
clinical practice might improve risk stratification, thereby further reducing TAVI-associated 
morbidity and mortality.
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inTROduCTiOn
Transcatheter aortic valve implantation (TAVI) has changed dramatically the treatment of severe 
aortic stenosis in inoperable patients or in patients at high risk for surgery. In the high risk 
population, particularly in the elderly, TAVI can offer a marked change in the life expectancy and 
quality of life of patients, and even nonagenarian patients can have successful valve replacement with 
acceptable periprocedural morbidity and mortality rates (1). However, early and late mortality after 
TAVI still remains relatively high. Results from registries and from the PARTNER trials reported 
1 year all-cause mortalities between 22 and 30% (2–4). In order to improve patient evaluation 
and minimize futility, risk models for poor outcomes post-TAVI have been built and validated, 
providing Heart teams with important decision-making tools and informations (5–8). Since the 
prognosis of patients who benefit the most from TAVI is often not only determined by severe 
symptomatic aortic stenosis (AS), but also by multiple comorbidities, it would still be very useful 
to have parameters or biomarkers that would help to better predict the risk of major cardiovascular 
events for these patients.
Here, we present an overview of the role of most studied blood biomarkers for predicting poor 
outcome post-TAVI (Figure  1). Despite recent procedural advances that improved safety and 
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help reducing further TAVI-associated morbidity and mortality, 
in a more personnalized manner.
Markers of Myocardial injury: Creatine 
Kinase Myocardial Band, Cardiac Troponin
Periprocedural elevation of cardiac biomarkers of myocardial 
injury is common in TAVI, with greater values observed following 
transapical or transaortic approaches compared to transfemoral 
(TF) approach (9). Higher levels of myocardial injury have been 
associated with reduced early and midterm survival following 
uncomplicated TAVI (10–13). Transapical (TA) procedure 
significantly associates with left ventricular apical fibrosis, 
contributing to apical wall motion abnormalities, which may, in 
turn, impair myocardial recovery (14).
TAVI clinical endpoints have been revisited in the current 
Valve Academic Research Consortium (VARC) −2 document 
(15), defining specific biomarker cut-off values for clinically 
significant myocardial infarction post-TAVI. In a large multicenter 
study of patients undergoing TAVI with different valve types and 
approaches, myocardial injury, determined by postprocedural 
rise in levels of creatine kinase myocardial band (CK-MB), was 
detected in two-third of patients undergoing TAVI, especially 
through transapical approach (16). Higher peak of CK-MB post-
TAVI translated into impaired systolic left ventricle function at 6 
to 12 months follow-up, and were associated with greater acute 
and late mortality (Table 1). Regarding cardiac troponin (cTn), 
correlation with patient outcome is less clear. Two small prospective 
studies of TF TAVI patients showed that baseline high sensitive TnT 
(hs-TnT) independently predicted survival in symptomatic high-
risk patients with severe AS (18, 22). Post-procedural hs-TnT rose 
significantly after TF TAVI until day 3, which had prognostic value 
for 1 year mortality. Determinants of post-procedural hs-TnT were 
baseline renal function, duration of intraprocedural rapid spacing, 
as well as pre-TAVI hs-TnT values (18). Despite hemodynamic 
relief, cTnT levels did not normalize even after months following 
successful TAVI, suggesting that the prognostic value of cTn for 
1 year patient outcome may rely on long-term changes in myocardial 
texture. A larger study indicated that cTnT elevation above VARC-2 
cut-off within 12 h post-procedure was a strong independent 
predictor of 30 day mortality, and remained significant at 2 years 
(17). In disagreement with these findings, a more recent study 
indicated that, in contrast to CK-MB, cTn elevation above normal 
limit defined by VARC-2 had no impact on late mortality of patients 
undergoing TF TAVI (23). Notably, VARC-2 cTnI cut-off values 
FiguRe 1 |  Blood biomarkers of TAVI-related myocardial injury, myocardial stretching, inflammation, and hemostasis imbalance that might provide postprocedural 
prognostic information. BNP, brain natriuretic peptide; CK-MB, creatinine kinase myocardial band; CRP, C-reactive protein; cTn, cardiac troponin; GDF-15, growth 
differentiation factor-15; HTPR, high on-treatment platelet reactivity; MPV, mean platelet volume.
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failed to distinguish myocardial injury from type 1 myocardial 
infarction (angiographically high-grade coronary artery stenoses 
or occlusions) in TF and TA TAVI patients, and therefore could 
not be used as a marker of periprocedural MI (24). Furthermore, 
different cut-offs may apply to TA and TF patients. These results 
should still be confirmed in larger randomized studies.
Markers of Myocardial Stretching: B-Type 
natriuretic Peptides
Elevation of circulating B-type natriuretic peptides (BNP) that 
results from left ventricle myocardial stretching is commonly used 
in clinics to predict the onset of symptoms and adverse events in 
patients with severe AS (25–27).
Several studies performed on TAVI patients have assessed the 
value of preprocedural or serial BNP or of its biologically inactive 
N-terminal-proBNP (NT-proBNP) as predictors of postprocedural 
outcome. Initial studies found no association of baseline BNP or 
NT-proBNP levels and 2 month mortality after TF or TA TAVI 
(28, 29). A high BNP level in high-risk patients with severe AS 
was not an independent marker for higher mortality. These two 
studies showed a transient increase of BNP levels from baseline to 
discharge, followed by a stepwise decrease until 1 year. The authors 
related the transient increase in BNP to the transient left ventricle 
dysfunction with depression of both systolic and diastolic left 
ventricular (LV) function associated with TAVI (30).
In contrast, a more recent study indicated that a high 
preprocedural BNP, and a rise in BNP at 30 days independently 
predicted 1 year outcome post-TF or transaxillary TAVI (20). This 
result was confirmed in another study from the PARTNER trial 
(19) showing that an increase of BNP at 30 days was a predictor of 
1 year mortality of transfemoral TAVI patients, as was moderate 
or severe aortic regurgitation over 1 year, and Society of Thoracic 
Surgeons (STS) score. Therefore, a rise in BNP at 30 days from 
baseline could provide prognostic information that should prompt 
careful clinical evaluation of these patients (Table 1).
Koskinas et al described an association between a high baseline 
BNP and a higher risk of all-cause death and cardiovascular death 
at 2 years, and a more frequent occurrence of VARC-2 clinical 
endpoints at 1 year (21). In this study, BNP levels increased 
or remained unchanged from baseline to discharge in 35% of 
patients, while these levels decreased in 65% of them. A baseline-
to-discharge decrease was related to New York Heart Association 
functional improvement. Patients with persistently high BNP before 
intervention and at discharge had increased rates of death at 2 years. 
The same authors compared the prognostic values of BNP and 
NT-proBNP, revealing superiority of postprocedural NT-proBNP 
to BNP as a predictor of all-cause mortality at 2 years. Another 
study analyzed the prognostic value of preprocedural NT-proBNP 
ratio, defined as the ratio of measured NT-proBNP to maximal 
normal NT-proBNP values specific for age and gender, on short- 
and long-term mortality (31). The authors showed that baseline 
NT-proBNP ratio could predict all-cause mortality at 30 days and 
1 year post-TAVI. Finally, in a later study, preinterventional levels 
of mid-regional (MR), pro-adrenomedullin (MR-proADM), and 
MR-pro-A-type natriuretic peptide (MR-proANP) and N-terminal 
pro-natriuretic peptide (NT-proBNP) were associated with 1 year 
cardiovascular events and all-cause mortality, while no association 
was found with 30 day outcome (32). Among most recently 
studied biomarkers, baseline levels of carbohydrate antigen 125 
were reported to be superior to NT-proBNP to predict adverse 
outcome of TAVI (33).
Thus, altogether these studies depict some prognostic value of 
periprocedural BNP in TAVI that should be validated in larger 
multicenter studies in order to foster their implementation in 
current clinical practice.
Markers of inflammation and Myocardial 
Stress
GDF-15
A prospective observational study was conducted that compared 
the prognostic value of risk scores (logistic European System for 
Cardiac Operative Risk Evaluation [EuroSCORE], EuroSCORE 
II, Society of Thoracic Surgeons predicted risk of mortality, and 
German aortic valve score) and circulating biomarkers (high-
sensitivity C-reactive protein [hsCRP], growth differentiation 
factor [GDF]-15, interleukin-6, interleukin-8, and NT-proBNP) 
to predict all-cause mortality and rehospitalization during the first 
year after TAVI (34). Strikingly, GDF-15, a cytokine belonging to 
the family of transforming growth factor-β, appeared to be the best 
predictor of poor outcome when added to the logistic EuroSCORE 
and EuroSCORE II.
These results are in agreement with another study in which high 
preintervention GDF-15 levels were associated with reduced time 
survival post-TAVI, and were superior to NT-proBNP for patient 
risk stratification (35). Interestingly, high GDF-15 levels were 
significantly associated with several variables of poor outcome, 
such as reduced kidney function, diabetes, STS score, high 
TABle 1 |  Proposed cut-off values of post-procedural biomarkers to predict mortality in TAVI.
Biomarker Cut-off effect References
CK-MB >UNL (within 3 days post-TAVI) ↑30 day and late mortality in overall and non-TA TAVI (11, 16)
>5 × UNL* (within 3 days post-TAVI) ↑30 day and late mortality in overall and non-TA TAVI
cTn >15 × UNL* (within 12 h post-TAVI) ↑30 day and 2 year mortality (overall TAVI) (17)
≥166 pg/ml (3 days post-TAVI) ↑1 year mortality (TF) (18)
BNP Rise at 30 days post-TAVI ↑1 year mortality in TF TAVI (19)
>328 pg/ml (30 days post-TAVI) ↑1 year mortality in TF and transaxillary TAVI (20)
≥591 pg/ml (persistent from baseline to discharge) ↑2 year mortality in overall TAVI (21)
UNL = upper normal limit based on the 99th percentile values in a healthy population *according to VARC-2
BNP, brain natriuretic peptide; CK-MB, creatine kinase-myocardial band; cTn, cardiac troponin; TA, transapical; TAVI, transcatheter aortic valve implantation; TF, transfemoral.
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creatinine and NT-proBNP levels, and VARC-2 criteria, suggesting 
that GDF-15 could integrate numerous complicating factors that 
could contribute to poor TAVI outcome.
Among eight biomarkers measured prior to valve replacement 
(GDF-15, soluble ST2 [sST2], NT-proBNP, galectin-3 [GAL-3], 
hs-cTnT, myeloperoxidase, hsCRP, and monocyte chemotactic 
protein-1 [MCP-1]), Lindman et al identified a combination 
of elevated levels of GDF-15, sST2 and NT-proBNP as the best 
predictors of 1 year mortality post-TAVI (36). However, since this 
study included both TAVI and patients who underwent surgical 
valve replacement, the utility of these three biomarkers should still 
be evaluated in specific populations of TAVI patients.
A recent study assessed the association of preprocedural BNP, 
hs-TnI, CRP, GDF-15, GAL-3, and cystatin-C with LV mycordial 
recovery with long-term all-cause mortality. Again, GDF-15 was 
strongly associated with all-cause mortality, as was CRP. GDF-15 
improved the risk model when added to the STS score. Though 
frailty has been associated with worse 1 year outcome post-TAVR, 
in this study, frailty alone was not superior to GDF-15 and did 
not significantly improve net reclassification when added to STS 
score. The authors also found that a lower baseline level of GDF-15 
predicted improvement of global longitudinal strain (GLS) at 1 year 
follow-up, which may partly explain the effect on survival. Notably, 
GLS at baseline was not as strongly related to outcome as GDF-15 
and CRP. GLS at 1 month could, however, predict 1 year mortality. 
In addition, this study uncovered an intriguing correlation between 
GDF-15 and left ventricular mass index.
Thus, baseline GDF-15 appears as a promising biomarker 
that could improve current risk prediction models for patients 
undergoing TAVI. Furthermore, these findings indicate that 
inflammation may play a major role in ventricular remodeling and 
recovery post-TAVI. Performing serial measurements of GDF-15 
and CRP would thus be interesting to determine the effect of the 
TAVI procedure on the progression of the inflammatory process, 
and its impact on patient outcome.
GDF-15 has been associated with multiple cardiovascular 
outcomes, possibly due to its pleiotropic effects on inflammation, 
oxidative stress, endothelial dysfunction, myocardial stress, and 
aging. Of particular interest, several studies reported an association 
of GDF-15 with a risk of major bleeding in acute coronary 
syndrome patients on dual antiplatelet therapy (37, 38). However, 
no studies have evaluated the possible role of GDF-15 in TAVI-
related bleeding events (see below), so far.
Markers of inflammation and Myocardial 
Stress
Soluble ST2
sST2 is an interleukin-1 receptor family member that acts as a 
decoy receptor for interleukin-33, and inhibits cardioprotective 
IL-33/ST2 signaling (39). Released following hemodynamic 
stress and cardiomyocyte strains (40), sST2 accurately predicts 
cardiovascular outcome of patients with acute and chronic 
heart failure. Consequently, sST2 was introduced in the ACC/
AHA guidelines for risk stratification of patients (41). Our 
team showed an association of sST2 with outcome in aortic 
stenosis (42).
 sST2 levels increase during the 24 h following TAVI, probably 
related to periprocedular myocardial dysfunction (30). Three 
studies recently indicated that preprocedural soluble ST2 might 
have long-term prognostic value after TAVI. The first study showed 
an association of baseline sST2 with 1 year mortality, with no effect at 
1 month (43). sST2 correlated significantly with echocardiographic 
parameters, CRP, creatinine, and BNP. In a second study, sST2 
was independently associated with 1 year mortality after TAVI, as 
were logistic EuroSCORE, chronic renal failure, and left ventricular 
ejection fraction (44). However, it was not superior to NT-proBNP 
or surgical risk scores (STS-PROM) for risk assessment, possibly 
due to confounding effect of inflammation on sST2 levels. In a 
third study, sST2 predicted mortality and the occurrence of major 
cardiovascular events post-TAVI (45). In contrast to the study of 
Stundl et al, adding sST2 to the STS score improved risk prediction 
of 2 year mortality.
Again, regarding sST2, future larger studies are awaited to 
validate these findings.
Markers of Hemostasis imbalance
In aortic stenosis, high shear stress through aortic valve induces 
a loss of high molecular weight von Willebrand factor (vWF) 
multimers (HMWM), platelet activation and release of platelet 
granule content (46). Increased activation of coagulation with 
concurrent hypofibrinolysis is also observed (47), all this 
contributing to the dual clinical picture of AS, characterized by 
mild bleeding tendency (48), and high thrombotic risk.
Thromboembolic events, primarily stroke, are serious 
complications of TAVI procedures, occurring in up to 3–5% of 
patients. In addition, TAVI causes thrombocytopenia in one-
third of patients. Importantly, while thrombocytopenia often 
resolves at discharge, persistent thrombocytopenia accurately 
predict 1 year mortality post-TAVI (49). Moreover, post-TAVI 
thrombocytopenia was found to be related to early post-procedural 
adverse events, including vascular complications, bleeding, and the 
need for multiple blood transfusions. To prevent TAVI-associated 
thromboembolic events and thrombocytopenia, a 3- to 6 month 
dual antiplatelet therapy (DAPT) is currently recommended for all 
approved balloon expandable and self-expandable transcatheter 
heart valve prostheses.
To determine which factors may explain the drop in platelet count 
that occurs after TAVI, Mitrosz et al (50) have prospectivelly analyzed 
changes in platelet count, along with markers of coagulation activation 
(F1 +2) and soluble markers of platelet activation (P-selectin, PF4) in a 
small cohort of severe AS, before TAVI and on the three postoperative 
days. While platelet reduction shortly after TAVI procedure was 
mostly influenced by the amount of contrast agent applied during 
the procedure, levels of PF4 and P-selectin positively correlated 
with the drop of platelet count, suggesting that thrombocytopenia 
is secondary to platelet activation. In-hospital major adverse 
cardiovascular events were observed more frequently in patients with 
more severe platelet count decrease (51). In another study, levels of 
thrombin-antithrombin complexes (TAT), plasmin-α₂-antiplasmin 
complex (PAP), and D-dimers significantly increased after TAVI, and 
D-dimer as well as PAP remained elevated until day 7, indicative of 
TAVI-induced increased thrombin formation and fibrinolysis (52). 
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Post-TAVI thrombocytopenia occurred in one-fifth of patients and 
was associated with a significantly higher incidence of post-TAVI 
complications, e.g., acute kidney injury and vascular complications, 
whereas no impact of activated coagulation on thrombocytopenia 
was observed.
Thus, altogether these studies indicate that consumption of activated 
platelets might be the mechanism leading to thrombocytopenia after 
TAVI. Therefore, periprocedural platelet activation markers may 
potentially represent predictors of adverse outcome.
Bleeding is a more common complication of TAVI than 
thromboembolic events, as major and life-threatening bleeding 
(MLTB) according to VARC-2 can occur in up to 30% of patients (53, 
54). Of note, periprocedural bleeding independently predicts all-
cause mortality after TAVI (53). High mean platelet volume (MPV) 
and low platelet distribution width (PDW) were associated with 
increased risk of any bleeding and MLTB (55). Since larger platelets 
are more reactive and are believed to increase thromboembolic 
risk (56–58), this finding may be surprising. However, it is possible 
that high MPV could be a consequence of patient’s health state, 
making them more prone to bleeding. It has been shown that 
MPV progressively normalizes during the days following TAVI, 
in parallel with NT-proBNP and hemodynamic parameters (59), 
but its relation with patient outcome has not been investigated yet.
Importantly, a decrease of platelet reactivity is probably not the 
only determinant of bleeding post-TAVI. Acquired von Willebrand 
disease may also play a role. However, to date, evidence for a link 
between vWF deficiency and overt bleeding in TAVI is lacking. 
Indeed, the loss of HMWM does not always associate with bleeding 
events after valve replacement (48, 60). Though, it has recently been 
shown that recovery of HMWM levels post-TAVI could be used 
as a marker of postprocedural paravalvular regurgitation, with a 
positive effect on 1 year mortality (61).
Finally, a high on-treatment platelet reactivity (HTPR) 
to clopidogrel, due to impaired response to this antiplatelet 
medication, appears to be very frequent in TAVI patients (62, 
63). Yet, no studies have evaluated the association of HTPR with 
post-TAVI outcomes. The ARTE randomized clinical trial showed 
a reduction of death, myocardial infarction, stroke, transient 
ischemic attack, or MLTB within the 3 months following TAVI 
with aspirin monotherapy versus DAPT (64). Thus, since there 
is currently no approved alternative to clopidogrel medication in 
>75 years TAVI patients (65), larger clinical trials aimed at defining 
the optimal antithrombotic regimen in these patients are awaited.
Strikingly, a recent study indicated that periprocedural changes 
in plasma markers of inflammation, interleukin-6 and S100A8/A9, 
could predict the decline in platelet count in the days following 
TAVI (66). A drop in platelet count and inhibition of agonist-
induced platelet activation occurred in parallel with an increase 
of the inflammation markers following valve deployment. Thus, 
the inflammatory process elicited by TAVI may contribute to 
postprocedural thrombocytopenia. This is in line with a study 
showing that severe systemic inflammatory response syndrome 
(SIRS) was related to higher 6 month all-cause mortality after TAVI 
(67). This concept warrants further investigation.
COnCluSiOn
In conclusion, blood biomarkers may enrich current risk scores 
in the future. BNP is readily available and easy to perform. Large 
studies will clarify the role of further markers.
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